Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2761074 | 1.00 | MEN1 (0.66) | MEN1KMT2AADORA3PRKAG1PRKAA1 | |
| SCHEMBL31685589 | 0.90 | MEN1 (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL3499237 | 0.89 | ADORA2A (0.64) | ADORA2AADORA2B | |
| SCHEMBL3499233 | 0.89 | ADORA2A (0.64) | ADORA2AADORA2B | |
| SCHEMBL5963062 | 0.87 | MEN1 (0.53) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL25097792 | 0.87 | MEN1 (0.73) | MEN1KMT2AADORA3PRKAG1PRKAA1 | |
| SCHEMBL29792955 | 0.87 | MEN1 (0.73) | MEN1KMT2AADORA3PRKAG1PRKAA1 | |
| SCHEMBL18503544 | 0.85 | MEN1 (0.74) | MEN1KMT2AADORA3ADORA1 | |
| SCHEMBL25098313 | 0.85 | MEN1 (0.74) | MEN1KMT2AADORA3ADORA1 | |
| SCHEMBL25097801 | 0.85 | MEN1 (0.74) | MEN1KMT2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986697-B1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE | GE HEALTHCARE DHARMACON INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20100184209-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| EP-1986697-A2 | COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE | Dharmacon, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007095387-A2 | COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070173476-A1 | MODIFIED POLYNUCLEOTIDES FOR USE IN RNA INTERFERENCE | DHARMACON INC. (US) | 2007-07-26 | — | — | US | disclosed |
| EP-1733035-A2 | MODIFIED POLYNUCLEOTIDES FOR REDUCING OFF-TARGET EFFECTS IN RNA INTERFERENCE | Dharmacon, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1718747-A2 | STABILIZED RNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS | Dharmacon, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005097992-A2 | MODIFIED POLYNUCLEOTIDES FOR REDUCING OFF-TARGET EFFECTS IN RNA INTERFERENCE | DHARMACON, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005078095-A1 | SNP DISCRIMINATORY siRNA | DHARMACON, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005078094-A2 | STABILIZED RNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS | DHARMACON, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173476-A1 | MODIFIED POLYNUCLEOTIDES FOR USE IN RNA INTERFERENCE | PHAX, NSUN2, RNMT | MEN1 3599/4885KMT2A 869/4885ADORA3 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.